Changchun High-Tech's GenSci 128 receives clinical trial approval

Changchun High & New Technology Industry Group (SZSE:000661) announced that its subsidiary, Changchun GeneScience Pharmaceutical, has received approval from the National Medical Products Administration for its GenSci 128 tablet clinical trial application. This approval paves the way for clinical trials of GenSci 128, a Class 1 innovative drug targeting the TP53 Y220C mutation found in locally advanced or metastatic solid tumors. GenSci 128 is a selective reactivator designed to bind with the TP53 Y220C mutated protein, restoring its normal conformation and tumor-suppressing function. The company believes this approval will broaden its business structure, optimize its product portfolio, and enhance its core competitiveness. While acknowledging potential uncertainties in the clinical trial process, the company has committed to disclosing future progress in accordance with regulations.